Clinical trials: Oesophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Role of Esophagectomy in Complete Responders to CCRT
To investigate the role of esophagectomy in complete responders to preoperative chemoradiotherapy for squamous cell carcinoma of esophagus, patients will be randomized to either observation or esophagectomy after concurrent…
- Trial name
- ESOPRESSO (NCT01740375)
- Testing
- esophagectomy
- Where
- South Korea
- Volunteers
- 486 people
- Sponsor
- Asan Medical Center
Esophageal Squamous Cell Carcinoma
Exploration and Verification of DNA Methylolation in Early Screening of Esophageal Cancer
The aim of this study was to detect the whole genome hydroxymethylation of peripheral blood ct DNA in normal population, patients with p0~pI esophageal squamous cell carcinoma and pII~pIV esophageal squamous cell carcinoma by…
- Trial name
- NCT03922230
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Esophageal Squamous Cell Carcinoma
Genome-wide Association Study
To explore biomarkers predictive of clinical response to Taxane/5-FU/platinum based chemotherapy in esophageal squamous cell carcinoma. To identify negative predictive markers to 5-FU/platinum/Taxane.
- Trial name
- NCT01498757
- Where
- South Korea
- Sponsor
- Samsung Medical Center
Esophageal Cancer, Nimotuzumab
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
Elderly or malnourished patients diagnosed with locally advanced esophageal squamous cell carcinoma (ESCC) had poor prognosis. Radiotherpy was an important and effective treatment in treating ESCC.
- Conditions
- Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy
- Trial name
- NCT06429839
- Testing
- Nimotuzumab with chemoradiotherapy
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Survivorship
Development and Validation of a Survival Prediction Model for Esophageal Cancer Patients After Esophagectomy
In this retrospective study, we analyzed data from the Sichuan Cancer Hospital \& Institute Esophageal Cancer Case Management Database (SCH-ECCM Database) from January 2010 to December 2017.
- Trial name
- OSmodel (NCT06169930)
- Testing
- This was an observational study without any intervention
- Where
- China
- Volunteers
- 2,957 people
- Sponsor
- Yongtao Han
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
This is a Phase 1/2a dose escalation and expansion study to determine the safety, tolerability, and preliminary clinical activity of 177LuBetaBart, a lutetium-labeled anti-B7-H3 monoclonal antibody, in patients with…
- Conditions
- Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer
- Trial name
- BetaBart (NCT07189871)
- Testing
- 177Lu-BetaBart, BetaBart + unlabeled BetaBart
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Radiopharm Theranostics, Ltd
Esophageal Squamous Cell Carcinoma
KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
This is an open-label, phase II study of KN046 combined with chemotherapy and palliative radiotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma to evaluate the safety, efficacy and tolerance.
- Trial name
- NCT03927495
- Testing
- KN046, palliative radiotherapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Chest Hospital
Esophagogastric Cancer, Esophagus Cancer
A Study of PET Scans With the Radioactive Tracer 18F-BMS-986229 in Patients With Esophageal, Stomach, or Gastroesophageal Junction Cancer
The purpose of the study is to test 18F-BMS-986229 positron emission tomography (PET) imaging a practical and safe way to check the status of esophageal, stomach, and gastroesophageal junction cancer.
- Conditions
- Esophagogastric Cancer, Esophagus Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT04161781
- Testing
- 18F-BMS-986229 Injection, IV 18F-BMS-986229, PET/CT Scan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Cancer, Solid Tumor
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
- Trial name
- NCT04672434
- Testing
- Sym021, Sym024
- Where
- 4 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Symphogen A/S
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Multimodal treatment combining surgery with chemotherapy and/or radiotherapy is necessary to improve the chances of survival in patients with locally advanced thoracic esophageal cancer.
- Trial name
- HCHTOG1903 (NCT04138212)
- Testing
- Paclitaxel, Cisplatin, neoadjuvant chemoradiation therapy
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Henan Cancer Hospital
Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
QL1706 in Combination With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced, Resectable Esophageal Squamous Cell Carcinoma
This is a randomized, double-blind, placebo-controlled Phase II/III clinical trial to evaluate the perioperative treatment with QL1706 in combination with neoadjuvant chemotherapy for locally advanced resectable esophageal…
- Trial name
- NCT06852456
- Testing
- Iparomlimab and Tuvonralimab (QL1706)Injection, Paclitaxel, Cisplatin
- Volunteers
- 30 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinoma
Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy for Esophageal Squamous Cell Carcinoma
This Phase II randomized study is to determine the efficacy of percutaneous endoscopic gastrostomy before definitive concurrent chemoradiotherapy (CCRT) in Patients with Esophageal Squamous Cell Carcinoma(ESCC) by assessing their…
- Trial name
- NCT04380480
- Testing
- Concurrent chemoradiotherapy combined with enteral feeding by percutaneous endoscopic gastrostomy
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma, Chemotherapy Effect
Predicting Postoperative Chemotherapy Efficacy in Patients With Esophageal Squamous Cell Carcinoma
Esophageal cancer remains a disease with a poor prognosis. Chemotherapy is an important part of its treatment, but there are cases in which chemotherapy is ineffective.
- Conditions
- Esophageal Squamous Cell Carcinoma, Chemotherapy Effect, DNA Methylation
- Trial name
- NCT06490003
- Testing
- Fluoro Uracil
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- City of Hope Medical Center
Esophageal Neoplasms
Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer
Histological Node Negative thoracic esophageal squamous cell carcinoma（pN0 ESCC） after radical resection still carries the risk of recurrence after complete surgical resection, especially in some high-risk patients.
- Trial name
- NCT02891083
- Testing
- Adjuvant chemotherapy (Paclitaxel and Cisplatin), Adjuvant radiotherapy, Control group (Surgery alone)
- Where
- China
- Volunteers
- 486 people
- Sponsor
- Shanghai Chest Hospital
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Esophagus Cancer
Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study
New tools are needed to 1) diagnose and 2) stage early esophageal squamous cell carcinoma (SCC) in order to improve outcomes of this frequent and lethal cancer.
- Trial name
- OESOCiTy (NCT03467529)
- Testing
- Non interventional study
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Nantes University Hospital
Resectable Esophageal Squamous Cell Carcinoma
Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Evaluating the efficacy and safety of PD-L1 (Programmed Death-L1)antibody combined with endoscopy and radiotherapy for inoperable cT1b-2 (clinical stage tumor 1b-2) esophageal squamous cell carcinoma
- Trial name
- NCT06599775
- Testing
- Adebrelimab injection, Albumin-Bound Paclitaxel, Carboplatin injection
- Volunteers
- 42 people
- Sponsor
- Shanghai Zhongshan Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Esophageal cancer is one of common malignant tumors in China and esophageal squamous cell carcinoma (ESCC) is the dominant pathological type, accounting for more than 95% of all cases.
- Trial name
- NCT02272699
- Testing
- Nimotuzumab, Paclitaxel, Cisplatin
- Where
- China
- Sponsor
- Peking University
Esophageal Cancer, Squamous Cell Carcinoma
Low-Dose Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum)/5-FU Combined With Radiation for Esophageal Cancer
The purpose of this study is to clarify efficacy and toxicity of daily low-dose Nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation in patients with esophageal squamous cell carcinoma.
- Trial name
- NCT00197444
- Testing
- CDGP/5-FU combined with radiation, Radiotherapy
- Where
- Japan
- Volunteers
- 33 people
- Sponsor
- Hamamatsu University
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
This is a Phase 1/2a open-label, multicenter, dose escalation and dose expansion trial in which IMT-009 will be administered by the intravenous (IV) route to participants with solid tumors or lymphomas.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Triple Negative Breast Cancer, Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT05565417
- Testing
- IMT-009, Fruquintinib
- Where
- 9 sites in United States
- Volunteers
- 67 people
- Sponsor
- Immunitas Therapeutics